Program
trastuzumab brengitecan
Also written as “BL-M07D1”, “T-Bren, Dose level 1” and “T-bren, Dose level 2”.
In Sichuan Biokin Pharmaceutical’s pipeline, HER2 ADC
. Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Urinary Bladder Neoplasms · Endometrial Neoplasms · Colorectal Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 2121 open or running | phase 3since Mar 12, 2024 | Jul 14, 2022 | Dec 2026phase 2 · NCT06114511 |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
T-Bren (BL-M07D1, HER2 ADC)
, phase 3, as of Nov 16, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 14, 2022.
- Feb 22, 2024Phase 1 study in Endometrial NeoplasmsNCT06293898 · 280 planned · United States
- Mar 12, 2024Phase 3 study in HER2-positive Breast CancerNCT06316531 · 274 enrolled · China
- May 16, 20242 phase 2 studiesNCT06423885, NCT06445400
- Feb 12, 2025Phase 3 study in HER2-positive Breast CancerNCT06830889 · 1,450 planned · China
- Mar 18, 2025Phase 3 study in HER2-positive Breast CancerNCT06891833 · 985 planned · China
- Apr 27, 2025Phase 3 study in HER2-low Breast CancerNCT06957886 · 566 planned · China
- Aug 26, 2025Phase 3 study in Gastric AdenocarcinomaNCT07152405 · 490 planned · China
- Sep 11, 2025Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07178795 · 440 planned · China
- Nov 24, 2025Phase 2 study in Non-squamous Non-small Cell Lung CancerNCT07264816 · 80 planned · China
- Apr 2, 20262 phase 3 studiesNCT07518173, NCT07545460
- May 19, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07606599 · 398 planned · China
- Jun 25, 2026Phase 2 study in Breast NeoplasmsNCT07678957 · 120 planned · China
- Jul 23, 2026Phase 3 study in Colorectal NeoplasmsNCT07730489 · 130 planned · China
- Oct 6, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07869836 · 520 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06114511
- Dec 2026Primary completion: phase 2 study in Her2-positive/Low-expression Urinary and Digestive Tract TumorsNCT06031584
- Dec 2026Primary completion: phase 1 study in Locally Advanced or Metastatic Digestive Tract TumorsNCT05631964
- Dec 2026Primary completion: phase 1 study in Breast NeoplasmsNCT05461768
TargetBeta
“HER2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07869836Urinary Bladder Neoplasms · United States | 3 | Recruiting | Dec 2028 | 520 |
| NCT07730489Colorectal Neoplasms · China | 3 | Not yet recruiting | Dec 2027 | 130 |
| NCT07678957Breast Neoplasms · China | 2 | Recruiting | Dec 2028 | 120 |
| NCT07606599Biliary Tract Neoplasms · China | 3 | Recruiting | Dec 2028 | 398 |
| NCT07545460Carcinoma, Ovarian Epithelial · China | 3 | Not yet recruiting | Dec 2028 | 404 |
| NCT07518173HER2-positive Breast Cancer · China | 3 | Recruiting | Dec 2029 | 596 |
| NCT07264816Non-squamous Non-small Cell Lung Cancer · China | 2 | Recruiting | Dec 2027 | 80 |
| NCT07178795Non-squamous Non-small Cell Lung Cancer · China | 3 | Recruiting | Dec 2027 | 440 |
| NCT07152405Gastric Adenocarcinoma · China | 3 | Recruiting | Jun 2027 | 490 |
| NCT06957886HER2-low Breast Cancer · China | 3 | Recruiting | May 2027 | 566 |
| NCT06891833HER2-positive Breast Cancer · China | 3 | Recruiting | Dec 2028 | 985 |
| NCT06830889HER2-positive Breast Cancer · China | 3 | Recruiting | Oct 2031 | 1,450 |
| NCT06445400HER2-positive Breast Cancer · China | 2 | Active, not recruiting | Jul 21, 2025 | 83 |
| NCT06423885HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma · China | 2 | Active, not recruiting | Oct 2026 | 64 |
| NCT06316531HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Oct 2026 | 274 |
| NCT06293898Endometrial Neoplasms · United States | 1 | Recruiting | Dec 15, 2028 | 280 |
| NCT06131450Gynecological Malignancies · China | 2 | Recruiting | Jan 2027 | 158 |
| NCT06114511Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Dec 2026 | 78 |
| NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors · China | 2 | Recruiting | Dec 2026 | 42 |
| NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors · China | 1 | Recruiting | Dec 2026 | 26 |
| NCT05461768Breast Neoplasms · China | 1 | Recruiting | Dec 2026 | 348 |
How it is read
Names in the registry
- “BL-M07D1”, 20 entries
- “T-Bren, Dose level 1”, 1 entry
- “T-bren, Dose level 2”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 8 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Urinary Bladder Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.